CY1116147T1 - Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2 - Google Patents

Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2

Info

Publication number
CY1116147T1
CY1116147T1 CY20151100136T CY151100136T CY1116147T1 CY 1116147 T1 CY1116147 T1 CY 1116147T1 CY 20151100136 T CY20151100136 T CY 20151100136T CY 151100136 T CY151100136 T CY 151100136T CY 1116147 T1 CY1116147 T1 CY 1116147T1
Authority
CY
Cyprus
Prior art keywords
subject
galaxy
threatening
identification
determination
Prior art date
Application number
CY20151100136T
Other languages
English (en)
Inventor
Yigal M Pinto
Original Assignee
Maastricht University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maastricht University filed Critical Maastricht University
Publication of CY1116147T1 publication Critical patent/CY1116147T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια μέθοδο για την ταυτοποίηση ενός υποκειμένου που κινδυνεύει να παρουσιάσει υπερτασική βλάβη τελικού οργάνου, όπως, και ειδικότερα, καρδιακή ανεπάρκεια, που περιλαμβάνει: α) την λήψη ενός βιολογικού δείγματος του εν λόγω υποκειμένου, β) τον προσδιορισμό του επιπέδου τουλάχιστον ενός μη-μυοκυτταρικού δείκτη στο εν λόγω δείγμα, γ) την σύγκριση του επιπέδου του εν λόγω δείκτη με ένα πρότυπο επίπεδο, και δ) τον προσδιορισμό, εάν το επίπεδο του δείκτη είναι ενδεικτικό ενός κινδύνου για την ανάπτυξη υπερτασικής βλάβης τελικού οργάνου. Ο μη-μυοκυτταρικός δείκτης είναι κατά προτίμηση γαλεκτίνη-3 ή θρομβοσπονδίνη-2.
CY20151100136T 2003-10-09 2015-02-12 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2 CY1116147T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP10186331.4A EP2317324B1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
CY1116147T1 true CY1116147T1 (el) 2017-02-08

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100108T CY1112359T1 (el) 2003-10-09 2012-02-01 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2
CY20151100136T CY1116147T1 (el) 2003-10-09 2015-02-12 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121100108T CY1112359T1 (el) 2003-10-09 2012-02-01 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2

Country Status (15)

Country Link
US (5) US7888137B2 (el)
EP (4) EP1522857A1 (el)
JP (5) JP4840744B2 (el)
CN (2) CN1879022B (el)
AT (1) ATE532073T1 (el)
AU (2) AU2004284496C1 (el)
CA (2) CA2842308A1 (el)
CY (2) CY1112359T1 (el)
DK (2) DK1682907T3 (el)
ES (2) ES2377012T3 (el)
HK (2) HK1101426A1 (el)
PL (2) PL2317324T3 (el)
PT (2) PT1682907E (el)
SI (2) SI1682907T1 (el)
WO (1) WO2005040817A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
JP2010504089A (ja) 2006-09-25 2010-02-12 ユニフェルジテイト・マーストリヒト 心不全を発生させる危険がある被検者を診断および／または処置するための手段および方法
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
JP2013536408A (ja) * 2010-07-02 2013-09-19 ビージー メディシン， インコーポレイテッド ガレクチン−３測定によりモニタリングされるスタチン療法
WO2012053305A1 (ja) * 2010-10-18 2012-04-26 岐阜市 筋萎縮性側索硬化症マーカー及びその利用
EP2460890A1 (en) 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
EP2671080A1 (en) * 2011-01-31 2013-12-11 BG Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN104011544B (zh) * 2011-12-08 2018-06-05 艾莱兹疗法股份有限公司 通过血浆去除术降低半乳凝素-3的水平
WO2014052803A2 (en) * 2012-09-27 2014-04-03 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
CA2973653A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
JP6612864B2 (ja) * 2015-05-28 2019-11-27 京セラ株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
ATE476662T1 (de) * 1997-09-05 2010-08-15 Southern Medical Diagnostics P Diagnoseverfahren
ATE298423T1 (de) * 1997-10-24 2005-07-15 Shionogi & Co Verfahren zur inhibierung des abbaus von natriuretischen peptiden und verbesserte methode zum bestimmen der natriuretischen peptide
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
DK1698901T3 (da) * 1999-01-29 2008-12-08 Roche Diagnostics Gmbh Metode til at detektere N-terminalt proBNP
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
AU6794700A (en) * 1999-08-20 2001-03-19 Board Of Regents, The University Of Texas System Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1358347A2 (en) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
AU2002218026A1 (en) * 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
AU2002226079A1 (en) * 2000-12-08 2002-06-18 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
US7041449B2 (en) 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
CA2483105C (en) * 2002-05-13 2011-05-10 Arexis Ab Autoimmune conditions and nadph oxidase defects
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20060257946A1 (en) 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
AU2006210794A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US20070092886A1 (en) 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法

Also Published As

Publication number Publication date
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
EP2919012A1 (en) 2015-09-16
US8084276B2 (en) 2011-12-27
CA2542033C (en) 2014-04-29
ES2377012T3 (es) 2012-03-21
CN102998458B (zh) 2015-07-22
US20080193954A1 (en) 2008-08-14
PL1682907T3 (pl) 2012-03-30
AU2004284496A1 (en) 2005-05-06
JP2014115297A (ja) 2014-06-26
PL2317324T3 (pl) 2015-10-30
EP1682907B1 (en) 2011-11-02
EP2317324B1 (en) 2014-11-12
US20130189716A1 (en) 2013-07-25
ATE532073T1 (de) 2011-11-15
AU2009227844B2 (en) 2012-07-19
CY1112359T1 (el) 2015-12-09
CN1879022B (zh) 2012-10-17
AU2009227844A1 (en) 2009-11-26
ES2530567T3 (es) 2015-03-03
EP2317324A1 (en) 2011-05-04
HK1184534A1 (zh) 2014-01-24
DK1682907T3 (da) 2012-08-13
JP2007508527A (ja) 2007-04-05
JP2011177184A (ja) 2011-09-15
JP4840744B2 (ja) 2011-12-21
US20120220532A1 (en) 2012-08-30
AU2004284496C1 (en) 2010-03-04
PT1682907E (pt) 2012-02-03
JP2010279378A (ja) 2010-12-16
SI1682907T1 (sl) 2012-03-30
EP1682907A1 (en) 2006-07-26
JP5580774B2 (ja) 2014-08-27
US20110104722A1 (en) 2011-05-05
WO2005040817A1 (en) 2005-05-06
CA2542033A1 (en) 2005-05-06
PT2317324E (pt) 2015-02-17
HK1101426A1 (en) 2007-10-18
US20150037353A1 (en) 2015-02-05
JP5789009B2 (ja) 2015-10-07
US7888137B2 (en) 2011-02-15
CN1879022A (zh) 2006-12-13
SI2317324T1 (sl) 2015-11-30
CN102998458A (zh) 2013-03-27
JP2015171365A (ja) 2015-10-01
EP1522857A1 (en) 2005-04-13
DK2317324T3 (en) 2015-02-16

Similar Documents

Publication Publication Date Title
CY1116147T1 (el) Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2
WO2004060278A3 (en) Methods for rapid identification of pathogens in humans and animals
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
WO2002087792A8 (en) Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles
ATE540319T1 (de) Verfahren für die bestimmung von fk506
ATE278805T1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
EP2293075A3 (en) Method for diagnosing neuro-degenerative disease
ATE111228T1 (de) Verfahren zur überwachung des kollagenabbaus.
EP1466985A3 (en) Methods for measuring bacteria, bacteria measuring apparatuses, and storage media for storing computer-executable programs for analyzing bacteria
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
DE602004025636D1 (de) Methode zur Beurteilung von rheumatoider Arthritis durch Bestimmung von Anti-CCP und Interleukin 6
ES2175095T3 (es) Marcadores de adn respecto al tamaño de una camada de cerdos.
ATE462001T1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
EE05634B1 (et) Geneetiline test kompleksset selgroo v„„rarengut kandvate veiste tuvastamiseks
DE50303798D1 (de) Vorrichtung, um in einem Zielgebiet eines menschlichen oder tierischen Körpers einen künstlichen isolierten Kreislauf zu etablieren
ATE330037T1 (de) Verfahren zur altersbestimmung von individuen
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
DK1381696T3 (da) Methods
FR2805545B1 (fr) Procede electrochimique de detection d'acides nucleiques
RU2001112840A (ru) Способ определения адаптивности селекционных образцов клевера лугового
PT912901E (pt) Metedo e reagentes para monitorizacao dos niveis sanguineos de compostos antiagregantes plaquetares
FR2834996B1 (fr) Methode d'identification de substances capables de moduler la differenciation adipocytaire
RU2003111869A (ru) Способ идентификации подлинности винодельческой продукции
WO2002018661A3 (en) Methods for identifying novel therapeutic agents